Neurogene (NASDAQ:NGNE) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Neurogene (NASDAQ:NGNE) posted its quarterly earnings data on Monday. The company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.05, Zacks reports. The firm had revenue of $0.93 million during the quarter.

Neurogene Trading Up 1.7 %

NASDAQ NGNE opened at $14.20 on Wednesday. The firm’s 50 day moving average price is $17.01 and its two-hundred day moving average price is $29.15. Neurogene has a twelve month low of $13.47 and a twelve month high of $74.49.

Insider Buying and Selling

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares of the company’s stock, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 9.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. HC Wainwright dropped their price target on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday. William Blair reissued an “outperform” rating on shares of Neurogene in a research note on Tuesday. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $59.80.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.